New York, United States - August 28, 2026 - Protheragen announced the release of its cosmetic analysis portfolio covering efficacy tests and cell‑based assays, supporting cosmetic manufacturers across product development, safety verification, and regulatory submission. With standardized pretreatment protocols, high‑precision instrumental analysis, and advanced in vitro cell models, Protheragen aims to give cosmetic developers reliable multi‑dimensional laboratory data throughout the whole product lifecycle.
Protheragen’s cosmetics testing covers a full spectrum of safety‑oriented detection methods, including microbial contamination screening, hazardous and restricted substance identification, preservative performance assessment, eye‑irritation HET‑CAM test and environmental‑safety fish embryo test. Given the diverse physical forms of cosmetic samples ranging from liquids, emulsions to pressed powders, Protheragen applies tailored sample pretreatment workflows. It combines classic preparation techniques such as liquid‑liquid extraction with advanced approaches including solid‑phase microextraction, accelerated solvent extraction and ultrasound‑assisted extraction to remove excipient interference and achieve accurate component measurement. Analytical instruments including LCMS and GCMS are deployed throughout the standardized workflow spanning initial consultation, sample handling, lab detection, formal report generation and post‑report technical follow‑up.
Complementing safety‑focused detection, Protheragen’s cosmetics efficacy tests deliver measurable data to validate product functional claims. The test scope spans moisturizing, sun‑protection SPF and PFA measurement, whitening‑freckle reduction, anti‑wrinkle, oil‑control and skin‑soothing evaluations, applicable to skincare, hair‑care, colour cosmetics and cleansing formulations. Real‑world human‑relevant patch tests are also incorporated into safety evaluation modules, helping cosmetic brands back up marketing claims with objective test evidence while meeting local regulatory requirements for cosmetic launch.
As an in vitro technical pillar, cell‑based assays for cosmetics explore ingredient mechanisms at the cellular level, filling gaps where conventional chemical or human‑subject tests cannot reach. Using reconstructed cell models such as keratinocytes, fibroblasts, B16 melanoma cells and SZ95 sebaceous gland cells, Protheragen carries out cytotoxicity screening, melanogenesis analysis, collagen synthesis monitoring, anti‑inflammatory assessment and skin‑barrier penetration studies. These assays evaluate anti‑aging, whitening, oil‑control, soothing and acne‑inhibiting performance of raw materials and finished formulas, enabling early‑stage safety and efficacy screening during R&D.
Protheragen cosmetics testing solutions can be deployed separately or combined into custom project packages according to clients’ product development timelines and compliance targets. Test reports contain raw analytical data, full‑procedure descriptions and corresponding regulatory references.
About Protheragen
Protheragen delivers specialized analytical and testing solutions for the cosmetics sector. Its laboratory team adopts streamlined pretreatment protocols, standardized analysis workflow and advanced cell-based assays to assist cosmetic enterprises with ingredient risk screening, finished‑product safety verification and functional‑claim validation.
Media Contact
Company Name: Protheragen
Contact Person: Hannah Green
Email: Send Email
Phone: 1-315-220-9688
Country: United States
Website: https://www.protheragen.ai/
